Health and Wellness CSR News

Do People in Developing Countries Have Access to Bayer Drug Products As Well?

Blog

Millions of people in developing countries have no access to medicines. In some cases they cannot afford them, while in others there simply are no markets and no functioning healthcare system. We are working to provide help in a number of ways. With our contraception access programs, for example, we aim to make self-determined family planning available to women in order to reduce maternal and infant mortality.

Profit Through Purpose: Eight Years of Pioneering and Learning

Unilever’s latest Sustainable Living Report shows how brands are innovating for impact
Article

April 16, 2019 - We’re eight years into our 10-year Unilever Sustainable Living Plan and have made significant progress across many of our ambitious targets.  We have also learnt a lot during that time. Not least that new technologies, new business models and new ways of thinking are all vital to creating the change the world needs – quickly and at scale. 

While we still face many challenges and don’t have all the answers, it’s clear that doing things differently will continue to be a key driver of our growth.

Special Ducks Help Comfort Children Who Are Battling Cancer

The ducks interact with kids, can be fed or bathed, and play soothing sounds, by Charlie Wojciechowski
Article

The invention, called “My Special Aflac Duck,” was named one of Time Magazine’s best inventions of 2018, and it’s easy to see why, as kids rapidly grow attached to them.

“We consider the duck a social robot,” inventor Aaron J. Horowitz said. “He is a constant companion for kids that can really share in the experience that they are having, and can give them a better tool to communicate how they feel.”

Read more here

Pfizer Reaffirms Commitment to Delivering Essential Therapies Through Manufacturing Investment

Article

We are experiencing an exciting new era in drug discovery and development with scientific advances that could result in future breakthroughs. To make this promise a reality, Pfizer is dedicated to investing in manufacturing capabilities to keep pace with science today, and to plan for what’s coming next.

350 Years of Curiosity Creating Shared Value

Article

April 16, 2019 - Merck KGaA, Darmstadt, Germany has published its tenth Corporate Responsibility Report, covering the year 2018. 

Europe-Africa Partnership Spearheads Development of Next-generation Antimalarial Drug

Summary: 
  • The European & Developing Countries Clinical Trials Partnership (EDCTP) grants €10 million over five years to “WANECAM 2” a unique collaboration between antimalarial drug researchers in Africa and Europe from ten academic institutions, a pharmaceutical company, Novartis, and a not-for-profit product development partnership (PDP), Medicines for Malaria Venture.
  • The grant will support African trials of a novel antimalarial combination comprising KAF156 (ganaplacide) and lumefantrine in a new once-daily formulation. KAF156 has demonstrated the potential to treat resistant malaria and to be administered as a single dose.
  • The grant will also help to build and strengthen research capabilities in the four participating African countries: Burkina Faso, Gabon, Mali and Niger.
Press Release
  • The European & Developing Countries Clinical Trials Partnership (EDCTP) grants €10 million over five years to “WANECAM 2” a unique collaboration between antimalarial drug researchers in Africa and Europe from ten academic institutions, a pharmaceutical company, Novartis, and a not-for-profit product development partnership (PDP), Medicines for Malaria Venture.
  • The grant will support African trials of a novel antimalarial combination comprising KAF156 (ganaplacide) and lumefantrine in a new once-daily formulation. KAF156 has demonstrated the potential to treat resistant malaria and to be administered as a single dose.
  • The grant will also help to build and strengthen research capabilities in the four participating African countries: Burkina Faso, Gabon, Mali and Niger.

The Drug Enforcement Administration, DEA Educational Foundation and Discovery Education Announce National Finalists for Third Annual ‘Operation Prevention’ Challenge

Public Invited to Vote for the 2019 People’s Choice Winner to Win Exclusive DEA Training Academy Tour
Press Release

SILVER SPRING, Md., April 11, 2019 /3BL Media/– The United States Drug Enforcement Administration (DEA), the DEA Educational Foundation, and Discovery Education, the leading provider of standards-aligned digital curriculum resources, engaging content, and professional learning for K-12 classrooms, today announced 10 national 2019 Operation Prevention Video Challenge finalists.

How Health Care Companies Can Advance Racial Equity and Strengthen Economic Performance

Press Release

April 16, 2019 /3BL Media/ Although many health care companies today claim that health equity is part of their overall mission, the efforts are still nascent and often focus on disparities caused by poverty, education, or disability. Many companies have efforts in diversity and inclusion, however, they are not sufficient to counter the effects of implicit biases in clinical practice or address the adverse social determinants of health that disproportionately affect populations of color.

Pages

Subscribe to Health and Wellness